EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort

Hao-I Hsieh iD, Yu-Nan Huang iD, Ya-Wen Chang, Wen-Ling Liao iD

Therapeutic Advances in Endocrinology and Metabolism · 2026-03 · 17

DOI: 10.1177/20420188261460619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 30.06.2026. Verfasst von Hao-I Hsieh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education, National Taiwan University Hospital, Taipei, Taiwan. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science and Technology Council, China Medical University Hospital, Chung Shan Medical University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used across the glycemic spectrum, yet their thyroid safety profile remains debated. Prior studies have shown inconsistent findings, and evidence across prediabetes, type 1 diabetes (T1D), and type 2 diabetes (T2D) is lacking.

Objectives

To evaluate diabetes-type-specific associations between GLP-1RA therapy and thyroid outcomes, including thyroid dysfunction, autoimmune thyroiditis, nontoxic goiter, and thyroid cancer.

Design

A real-world, retrospective target-trial emulation using electronic health records (EHR) from a large multicenter network.

Methods

We used the TriNetX US Collaborative Network to identify adults with prediabetes, T1D, or T2D initiating GLP-1RAs. Active comparators included usual care and sodium–glucose cotransporter two inhibitors (SGLT2i). Propensity score matching with extensive covariate adjustment was applied. Participants were followed for incident thyroid outcomes for up to 5 years. Sensitivity and subgroup analyses were conducted to assess robustness.

Results

Across glycemic states, GLP-1RA therapy demonstrated distinct thyroid safety patterns. In prediabetes and T1D, GLP-1RA use was associated with reduced risks of thyroid dysfunction and all-cause mortality, suggesting potential metabolic or immunomodulatory benefits. By contrast, among individuals with T2D, GLP-1RA exposure was linked to modest increases in autoimmune thyroiditis and nontoxic goiter, particularly among those with obesity or without hypertension. Importantly, no increased risk of thyroid cancer was observed in any glycemic state, providing reassuring evidence regarding long-term endocrine safety.

Conclusion

In this large-scale target-trial emulation, GLP-1RAs showed favorable thyroid safety profiles in prediabetes and T1D, while modestly increasing selected nonmalignant thyroid outcomes in T2D. The absence of elevated thyroid cancer risk across glycemic states supports the overall endocrine safety of GLP-1RAs. These findings highlight the importance of individualized monitoring, particularly in metabolically high-risk T2D populations.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistsglycemic statesprediabetesreal-world evidencethyroid safetytype 1 diabetestype 2 diabetes

Autor:innen und Institutionen

  • Department of Education, National Taiwan University Hospital, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, Chung Shan Medical University; Taichung, Taiwan.
  • Department of Life Science, National Chung Hsing University, Taichung, Taiwan.
  • Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.

ORCID-Profile: Hao-I Hsieh, Yu-Nan Huang, Wen-Ling Liao

Förderung

  • National Science and Technology Council
  • China Medical University Hospital
  • Chung Shan Medical University Hospital

Zitieren

APA

Hsieh, H. I., Huang, Y. N., Chang, Y. W., & Liao, W. L. (2026). Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort. Therapeutic Advances in Endocrinology and Metabolism, 17. https://doi.org/10.1177/20420188261460619

Vancouver

Hsieh HI, Huang YN, Chang YW, Liao WL. Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort. Therapeutic Advances in Endocrinology and Metabolism. 2026;17. doi:10.1177/20420188261460619

BibTeX
@article{Hsieh2026,
  author = {Hsieh, Hao-I and Huang, Yu-Nan and Chang, Ya-Wen and Liao, Wen-Ling},
  title = {Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort},
  journal = {Therapeutic Advances in Endocrinology and Metabolism},
  year = {2026},
  volume = {17},
  doi = {10.1177/20420188261460619}
}
Kostenlos starten →